NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination.
The editorial places Quantum BioPharma alongside companies advancing therapies across areas of unmet medical need, including Novartis AG (NYSE: NVS), which received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer; Merck & Co. Inc. (NYSE: MRK), whose supplemental Biologics License Application for ENFLONSIA(TM) was accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease; TG Therapeutics Inc. (NASDAQ: TGTX), which initiated a phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia; and Bristol-Myers Squibb Company (NYSE: BMY), which reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
To view the full press release, visit https://nnw.fm/lCey9
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (“MS”) following U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (“PAD2”) designed to target demyelination directly rather than suppress the immune system. The editorial also highlights Quantum BioPharma research collaboration with Massachusetts General Hospital and Harvard Medical School involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination.
The editorial places Quantum BioPharma alongside companies advancing therapies across areas of unmet medical need, including Novartis AG (NYSE: NVS), which received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer; Merck & Co. Inc. (NYSE: MRK), whose supplemental Biologics License Application for ENFLONSIA(TM) was accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease; TG Therapeutics Inc. (NASDAQ: TGTX), which initiated a phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia; and Bristol-Myers Squibb Company (NYSE: BMY), which reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
To view the full press release, visit https://nnw.fm/lCey9
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
